Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Oct 27, 2026; 18(10): 121168
Published online Oct 27, 2026. doi: 10.4240/wjgs.121168
Published online Oct 27, 2026. doi: 10.4240/wjgs.121168
Table 3 Comparison of survival outcomes between patients with pathological remission, n (%)
| Response | Number of patients | Recurrence or metastasis | Deaths | 1-year DFS (%) | 1-year OS (%) | Log-rank | P value (DFS) | Log-rank | P value (OS) |
| pCR group (TRG 0) | 30 | 1 (3.3) | 0 (0.0) | 96.7 | 100.0 | 28.652 | < 0.001 | 25.321 | < 0.001 |
| MPR group (TRG 1) | 30 | 4 (13.3) | 2 (6.7) | 88.3 | 95.0 | ||||
| Non-MPR group (TRGs 2 and 3) | 70 | 14 (20.0) | 8 (11.4) | 65.0 | 77.5 | ||||
| Total | 130 | 19 (14.6) | 10 (7.7) | 85.4 | 92.3 |
- Citation: Zhang K, Li ZJ. Correlation between pathological response to neoadjuvant immunotherapy and long-term survival in locally advanced rectal cancer: A real-world study. World J Gastrointest Surg 2026; 18(10): 121168
- URL: https://www.wjgnet.com/1948-9366/full/v18/i10/121168.htm
- DOI: https://dx.doi.org/10.4240/wjgs.121168